Ryogen LLC, a genomic start-up company, has been awarded a new patent titled “Isolated Genomic Polynucleotide Fragments from Chromosome 7”.
U.S. patent No. 7,588,915, issued by the U.S. Patent and Trademark Office, claims isolated genomic polynucleotide fragments that encode human adipocyte enhancer binding protein 1 (AEBP1), complementary polynucleotides, vectors and host cells containing these fragments and a method for obtaining AEBP1.
“The protein encoded by the claimed sequences is thought to play a role in diabetes and metabolic syndrome, obesity, inflammation, immune processes, osteopenia and atherogenesis,” says Dr. James W. Ryan, the named inventor and Ryogen’s Chief Scientist.
“The new patent is an important addition to Ryogen’s intellectual property portfolio,” says Valeria Poltorak, the company’s Executive Vice President. “We are planning to offer this patent for licensing to make it widely available to researchers to facilitate the development of new diagnostic and treatment methods,” she adds.
BindCraft reimagines protein binder discovery through structural prediction